Department of Radiology, Research Institute of Radiological Science, Yonsei University Health System, Seoul, Republic of Korea.
J Magn Reson Imaging. 2011 Sep;34(3):570-6. doi: 10.1002/jmri.22696. Epub 2011 Jul 12.
To compare diffusion-weighted imaging (DWI) and magnetic resonance (MR) volumetry for predicting treatment outcomes of locally advanced rectal cancers with preoperative chemoradiotherapy (CRT).
This prospective study was approved by our Institutional Review Board. Thirty-four patients underwent three MR examinations: pre-CRT (before CRT), early CRT (2 weeks after CRT initiation), and post-CRT (before surgery). The tumor apparent diffusion coefficient (ADC), ADC increase rate, and volume reduction rate were compared between responders and nonresponders using three reference standards: downstaging, modified Response Evaluation Criteria in Solid Tumors (mRECIST), and tumor regression grade (TRG). For DWI and volumetry, differences between responders and nonresponders were assessed by receiver operating characteristic analysis.
The median early tumor volume reduction rate of responders, subgrouped by downstaging and mRECIST (47.97% and 53.97%, respectively), was significantly higher than that of nonresponders (20.94% and 20.36%; P = 0.0024 and 0.0001, respectively), but there were no significant differences in pre-CRT ADC and early ADC increase rate using all references. When using the downstaging and mRECIST, the diagnostic performance of early tumor volume reduction rate (Az = 0.81 and 0.94, respectively) was higher than that of pre-CRT ADC (Az = 0.55 and 0.62; P = 0.033 and 0.007) and early ADC increase rate (Az = 0.58 and 0.64; P = 0.055 and 0.01) for predicting the treatment outcome. For TRG, there were no significant differences between DWI and volumetry.
Early tumor volume reduction rate at the second week after CRT initiation may be a better indicator than DWI based on the mean ADC measurements for predicting CRT treatment outcome.
比较弥散加权成像(DWI)和磁共振(MR)体积测量在预测接受术前放化疗(CRT)的局部进展期直肠癌治疗效果中的作用。
本前瞻性研究经我院伦理委员会批准。34 例患者接受了 3 次 MR 检查:CRT 前(CRT 前)、早期 CRT(CRT 开始后 2 周)和 CRT 后(手术前)。使用降期、改良实体瘤疗效评价标准(mRECIST)和肿瘤退缩分级(TRG)这 3 种参考标准,比较应答者和无应答者之间的肿瘤表观扩散系数(ADC)、ADC 增长率和体积减少率。通过受试者工作特征分析评估 DWI 和体积测量在应答者和无应答者之间的差异。
应答者(降期和 mRECIST 亚组)的早期肿瘤体积减少率中位数分别为 47.97%和 53.97%,显著高于无应答者(分别为 20.94%和 20.36%;P=0.0024 和 0.0001),但使用所有参考标准,早期肿瘤 ADC 和早期 ADC 增长率均无显著差异。使用降期和 mRECIST 时,早期肿瘤体积减少率的诊断性能(Az 值分别为 0.81 和 0.94)高于早期肿瘤 ADC(Az 值分别为 0.55 和 0.62;P=0.033 和 0.007)和早期 ADC 增长率(Az 值分别为 0.58 和 0.64;P=0.055 和 0.01),可用于预测治疗效果。对于 TRG,DWI 和体积测量之间无显著差异。
与基于平均 ADC 测量的 DWI 相比,CRT 开始后第 2 周的早期肿瘤体积减少率可能是预测 CRT 治疗效果的更好指标。